熱門資訊> 正文

Lyell Immunoglobulma报告第二季度结果

2025-08-13 05:06

Lyell Immunopharma press release (NASDAQ:LYEL): Q2 net loss of $42.7 million
Revenue of $8K, vs. $13K a year ago

More on Lyell Immunopharma

Lyell: 'Hold' Rating Based On Phase 3 LYL314 LBCL Treatment Program Advancement
Lyell Immunopharma announces up to $100 million equity private placement
Lyell Immunopharma strengthens clinical and commercial capabilities with executive appointments
Seeking Alpha’s Quant Rating on Lyell Immunopharma
Historical earnings data for Lyell Immunopharma

推薦文章

風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。